Current landscape of clinical management for systemic light chain amyloidosis.
作者信息
Staron Andrew, Sanchorawala Vaishali
机构信息
Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USA.
Section of Hematology & Oncology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USA.
出版信息
Future Cardiol. 2025 Mar;21(4):203-205. doi: 10.1080/14796678.2025.2460392. Epub 2025 Jan 31.
Abstract
摘要
相似文献
1
Current landscape of clinical management for systemic light chain amyloidosis.系统性轻链淀粉样变性的临床管理现状
Future Cardiol. 2025 Mar;21(4):203-205. doi: 10.1080/14796678.2025.2460392. Epub 2025 Jan 31.
2
Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry.瑞士淀粉样变性登记处患者的历史特征和死亡率。
Swiss Med Wkly. 2024 Feb 15;154:3485. doi: 10.57187/s.3485.
3
A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.系统性轻链淀粉样变患者死亡率变化的研究现状
JACC Heart Fail. 2019 Nov;7(11):958-966. doi: 10.1016/j.jchf.2019.07.007. Epub 2019 Oct 9.
4
Integrated specialty care for amyloidosis: a scoping review using the Consolidated Framework for Implementation Research.淀粉样变性的综合专科护理：一项使用实施研究综合框架的范围综述。
BMC Health Serv Res. 2025 Mar 21;25(1):415. doi: 10.1186/s12913-025-12520-3.
5
Disease burden of systemic light-chain amyloidosis: a systematic literature review.系统性轻链淀粉样变性的疾病负担：一项系统文献综述。
Curr Med Res Opin. 2017 Jun;33(6):1017-1031. doi: 10.1080/03007995.2017.1297930. Epub 2017 Apr 11.
6
Navigating Diagnostic Ambiguities in Cardiac Amyloidosis: Insights from a Case with Delayed Diagnosis of AL Amyloidosis.心脏淀粉样变性诊断中的模糊性解析：一例AL型淀粉样变性延迟诊断病例的启示
Am J Case Rep. 2025 Jul 4;26:e948092. doi: 10.12659/AJCR.948092.
7
Role of Autologous Stem Cell Transplantation in Systemic Light Chain Amyloidosis.自体干细胞移植在系统性轻链淀粉样变性中的作用。
Clin Lymphoma Myeloma Leuk. 2024 Nov;24(11):770-777. doi: 10.1016/j.clml.2024.06.009. Epub 2024 Jul 2.
8
The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in China.中国系统性轻链淀粉样变的临床表现和治疗管理。
Kidney Dis (Basel). 2016 Apr;2(1):1-9. doi: 10.1159/000444287. Epub 2016 Feb 25.
9
Supportive Care in AL Amyloidosis.AL 淀粉样变中的支持性治疗。
Acta Haematol. 2020;143(4):335-342. doi: 10.1159/000506760. Epub 2020 Apr 1.
10
Immunoglobulin Light Chain Systemic Amyloidosis.免疫球蛋白轻链系统性淀粉样变性
Cancer Treat Res. 2016;169:273-318. doi: 10.1007/978-3-319-40320-5_15.
本文引用的文献
1
Factors impeding organ recovery despite a deep haematological response in patients with systemic AL amyloidosis.尽管系统性AL淀粉样变性患者有深度血液学反应，但阻碍器官恢复的因素。
Br J Haematol. 2024 Dec;205(6):2268-2272. doi: 10.1111/bjh.19766. Epub 2024 Sep 14.
2
Anticoagulation in Atrial Fibrillation Associated With Cardiac Amyloidosis: A Narrative Review.心脏淀粉样变性伴发心房颤动的抗凝治疗：一篇叙述性综述
Cureus. 2024 Jun 3;16(6):e61557. doi: 10.7759/cureus.61557. eCollection 2024 Jun.
3
Systemic Light Chain Amyloidosis.系统性轻链型淀粉样变性
N Engl J Med. 2024 Jun 27;390(24):2295-2307. doi: 10.1056/NEJMra2304088.
4
Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.晚期心脏淀粉样变性患者的治疗反应和生存结局的预测因素。
Blood Adv. 2023 Oct 24;7(20):6080-6091. doi: 10.1182/bloodadvances.2023010324.
5
Factors affecting the accuracy of amyloidosis identification and referral to a specialty centre.影响淀粉样变识别和转诊至专业中心准确性的因素。
Amyloid. 2023 Sep;30(3):297-302. doi: 10.1080/13506129.2023.2171787. Epub 2023 Jan 31.
6
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.系统性轻链淀粉样变患者的心脏反应分级标准。
J Clin Oncol. 2023 Mar 1;41(7):1393-1403. doi: 10.1200/JCO.22.00643. Epub 2022 Oct 10.
7
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study.干细胞移植治疗淀粉样变性的血液学反应和生存预测因素：25 年的纵向研究。
Am J Hematol. 2022 Sep;97(9):1189-1199. doi: 10.1002/ajh.26641. Epub 2022 Jul 5.
8
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines.系统性淀粉样变高剂量化疗和干细胞移植治疗指南：EHA-ISA 工作组指南。
Amyloid. 2022 Mar;29(1):1-7. doi: 10.1080/13506129.2021.2002841. Epub 2021 Nov 16.
9
Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab.达雷妥尤单抗治疗淀粉样变性患者结局的预测因素。
Am J Hematol. 2022 Jan 1;97(1):79-89. doi: 10.1002/ajh.26399. Epub 2021 Nov 15.
10
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study.AL 淀粉样变性生存的显著进展：一项 40 年的纵向自然史研究。
Blood Cancer J. 2021 Aug 4;11(8):139. doi: 10.1038/s41408-021-00529-w.
Zotero 插件